+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Medications for Alzheimer's Disease Market - Global Forecast 2025-2030- Product Image
Medications for Alzheimer's Disease Market - Global Forecast 2025-2030- Product Image
Sale

Medications for Alzheimer's Disease Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6120640
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Alzheimer’s Disease therapeutics market is undergoing rapid transformation, marked by advancing scientific innovation, evolving regulatory frameworks, and increased focus on patient-centric care. Senior decision-makers face critical choices as stakeholders adapt sourcing, pricing, and commercialization strategies to a dynamic environment shaped by technology, real-world evidence, and shifting global trade policies.

Market Snapshot: Alzheimer’s Disease Therapeutics Landscape

The Alzheimer’s Disease therapeutics sector is at a critical juncture, defined by pivotal clinical evidence, significant regulatory adaptation, and rising patient needs. Market momentum is fueled by breakthroughs in molecular biology, real-time data provided by digital health tools, and the pressing demand for therapies that move beyond symptom management. Stakeholders across the pharmaceutical value chain—including drug manufacturers, healthcare providers, and payers—are responding with agile operational models and targeted investment in disease-modifying treatments. Successful navigation of this marketplace depends on understanding the convergence of market drivers, technology advances, and evolving reimbursement expectations.

Scope & Segmentation

This report delivers a comprehensive analysis of the Alzheimer’s Disease therapeutics market, offering granular insights across treatment options, technology use, and regional dynamics.

  • Drug Classes: Acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine), NMDA receptor antagonists (memantine), and combination therapies (donepezil-memantine).
  • Formulations: Oral (tablets, capsules, liquids), injectable (intravenous, intramuscular), and transdermal patches.
  • Patient Severity Levels: Mild, moderate, and severe cognitive decline.
  • Distribution Channels: Hospital, online, and retail pharmacies, including both chain and independent outlets.
  • Brand Types: Branded therapies (Aricept, Ebixa, Exelon Patch) and generic drugs (donepezil, galantamine, rivastigmine, memantine).
  • End Users: Clinics, hospitals, and home care providers.
  • Regions Analyzed: Americas (with detailed coverage for the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including more than 15 countries), and Asia-Pacific (covering China, India, Japan, South Korea, and other high-growth markets).
  • Leading Companies: Eisai Co., Ltd.; Pfizer Inc.; Allergan plc; Novartis International AG; Johnson & Johnson; Biogen Inc.; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Viatris Inc.

Key Takeaways: Strategic Insights for Decision-Makers

  • Precision medicine and biomarker-guided interventions are expanding early-stage diagnosis and driving development of disease-modifying therapies.
  • Digital health innovations, such as remote monitoring and real-world data platforms, are reshaping clinical trial design and patient engagement strategies.
  • Regulatory shifts, including accelerated and conditional approval pathways, are prompting manufacturers to adopt new evidence-generation and risk-sharing models with payers.
  • Manufacturers’ response to 2025 United States tariff policies includes rerouting supply and enhancing local manufacturing to stabilize pricing and ensure supply chain resilience.
  • Regional variation in market access is pronounced, requiring tailored partnerships, particularly in resource-constrained geographies or emerging markets.
  • Competitive dynamics reflect ongoing M&A consolidation, strategic collaborations between pharma and biotech, and the emergence of digital therapeutic entrants supporting adherence and value-based care.

Primary Keyword: Alzheimer’s Disease therapeutics

Tariff Impact: Reshaping Sourcing and Pricing Strategies

The implementation of United States tariffs in 2025 has directly impacted sourcing for both active pharmaceutical ingredients and finished treatments. Companies have adapted by diversifying procurement channels, emphasizing domestic and tariff-exempt supplies, and investing in local manufacturing capacity. These measures have influenced downstream pricing negotiations and reimbursement structures, fueling the adoption of value-based agreements and heightened scrutiny of health economics throughout product development.

Methodology & Data Sources

Research findings were derived from a multi-stage process, integrating comprehensive reviews of peer-reviewed journals, regulatory sources, and clinical trial registries with primary data from expert interviews, physician and payer surveys. Data triangulation and advanced statistical analysis ensured robust correlation across treatment preferences, adherence metrics, and channel utilization. Competitive benchmarking was performed using pipeline documentation and licensing disclosures.

Why This Report Matters

  • Enables strategic planning by providing actionable insights aligned with evolving drug development paradigms, payer expectations, and regulatory pathways.
  • Offers objective analysis to optimize market entry, expand patient access, and leverage technology-driven competitive differentiation.
  • Supports risk mitigation through clear assessment of regional access barriers, tariff impacts, and stakeholder dynamics.

Conclusion

As Alzheimer’s Disease therapeutics enter a new era, agility, rigorous evidence generation, and patient-centric strategies are essential for sustainable growth. Senior leaders will benefit from proactive adaptation to regulatory, technological, and market shifts to drive meaningful therapeutic progress.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of digital biomarkers and AI-driven diagnostics to personalize Alzheimer’s therapy selection
5.2. Expansion of blood-based amyloid and tau assays to accelerate early Alzheimer’s diagnosis in clinical practice
5.3. Ongoing evaluation of low-dose CT and PET imaging comparators to optimize cost-effective Alzheimer’s disease monitoring
5.4. Development of combination therapeutic regimens targeting neuroinflammation and synaptic repair for Alzheimer’s disease patients
5.5. Market entry strategies for emerging small molecule tau aggregation inhibitors in competitive neurology pipelines
5.6. Impact of value-based contracting and real-world evidence generation on Alzheimer’s medication pricing and access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Medications for Alzheimer's Disease Market, by Drug Class
8.1. Introduction
8.2. Acetylcholinesterase Inhibitors
8.2.1. Donepezil
8.2.2. Galantamine
8.2.3. Rivastigmine
8.3. Combination Therapy
8.3.1. Donepezil Memantine Combination
8.4. Nmda Receptor Antagonists
8.4.1. Memantine
9. Medications for Alzheimer's Disease Market, by Formulation
9.1. Introduction
9.2. Injectable
9.2.1. Intramuscular
9.2.2. Intravenous
9.3. Oral
9.3.1. Capsule
9.3.2. Liquid
9.3.3. Tablet
9.4. Transdermal Patch
10. Medications for Alzheimer's Disease Market, by Patient Severity
10.1. Introduction
10.2. Mild
10.3. Moderate
10.4. Severe
11. Medications for Alzheimer's Disease Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.4.1. Chain Pharmacy
11.4.2. Independent Pharmacy
12. Medications for Alzheimer's Disease Market, by Brand Type
12.1. Introduction
12.2. Branded
12.2.1. Aricept
12.2.2. Ebixa
12.2.3. Exelon Patch
12.3. Generic
12.3.1. Generic Donepezil
12.3.2. Generic Galantamine
12.3.3. Generic Memantine
12.3.4. Generic Rivastigmine
13. Medications for Alzheimer's Disease Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
14. Americas Medications for Alzheimer's Disease Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Medications for Alzheimer's Disease Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Medications for Alzheimer's Disease Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Eisai Co., Ltd.
17.3.2. Pfizer Inc.
17.3.3. Allergan plc
17.3.4. Novartis International AG
17.3.5. Johnson & Johnson
17.3.6. Biogen Inc.
17.3.7. Eli Lilly and Company
17.3.8. Teva Pharmaceutical Industries Ltd.
17.3.9. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET: RESEARCHAI
FIGURE 28. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET: RESEARCHSTATISTICS
FIGURE 29. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET: RESEARCHCONTACTS
FIGURE 30. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GALANTAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DONEPEZIL MEMANTINE COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DONEPEZIL MEMANTINE COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MEMANTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ARICEPT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ARICEPT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY EBIXA, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY EBIXA, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY EXELON PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY EXELON PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC GALANTAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC GALANTAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC MEMANTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC MEMANTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 169. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 174. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 175. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 176. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 177. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 180. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 181. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 182. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 183. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 184. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 185. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 188. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 189. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 190. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 191. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 192. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 193. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 194. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 195. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. CANADA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 202. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 203. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 206. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 207. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 210. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 211. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 212. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 213. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 216. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 217. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 218. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 219. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 220. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 221. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 222. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 223. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. MEXICO MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY PATIENT SEVERITY, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRAND TYPE, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY BRANDED, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY GENERIC, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY ACETYLCHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALZHEIMER'S DISEASE MARKET SIZE, BY FORM

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Medications for Alzheimer's Disease market report include:
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Allergan plc
  • Novartis International AG
  • Johnson & Johnson
  • Biogen Inc.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Related Topics

Related Reports

Alzheimer's Disease Drugs Market - Global Forecast 2025-2030 - Product Image

Alzheimer's Disease Drugs Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Alzheimer'S Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2025-2033 - Product Image

Alzheimer'S Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Alzheimer's Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Alzheimer's Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Alzheimer's Disease Drugs - Global Strategic Business Report - Product Image

Alzheimer's Disease Drugs - Global Strategic Business Report

  • Report
  • 189 Pages
  • Global
From
Alzheimer's Treatment Market Report and Forecast 2025-2034 - Product Image

Alzheimer's Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.